drugset
Drugs / RTS,S/AS01B
last change Nov 2017 re-read 3 minutes ago

RTS,S/AS01B

also known as RTS,S

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline · The PATH Malaria Vaccine Initiative (MVI) · Walter Reed Army Institute of Research (WRAIR)

Trials 1

today NCT01857869 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01857869 May 2013 → Mar 2014 malaria GlaxoSmithKline Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as RTS,S/AS01B “RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group).” NCT01857869 ↗
Known as RTS,S “The current leading candidate, RTS,S, is a recombinant circumsporozoite protein (CSP)-based vaccine against Plasmodium falciparum” PMID 29138320 ↗ Nov 2017
Modality Vaccine “malaria candidate vaccine 257049” NCT01857869 ↗